Clinical trials: Patients with Advanced Solid Tumors
Advanced Solid Tumors, Cholangiocarcinoma
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors
- Trial name
- NCT06370013
- Testing
- Tinengotinib
- Where
- 5 sites in United States
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors
Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom…
- Trial name
- NCT00426582
- Testing
- Patupilone
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI 8993 for administration to patients with relapsed/refractory solid tumors by evaluating the safety and tolerability and characterizing…
- Trial name
- NCT04475523
- Testing
- CI-8993
- Where
- 6 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- Curis, Inc.
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.
- Trial name
- NCT03700294
- Testing
- ADCT-601
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ADC Therapeutics S.A.
Cancer
PTC596 in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic study of PTC596 in patients with advanced cancer.
- Trial name
- NCT02404480
- Testing
- PTC596
- Where
- 4 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- PTC Therapeutics
Unspecified Adult Solid Tumor, Protocol Specific
Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors
RATIONALE: Angiotensin-(1-7) may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of angiotensin-(1-7) in treating patients with…
- Trial name
- NCT00471562
- Testing
- therapeutic angiotensin-(1-7)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
A Study of APX3330 in Patients With Advanced Solid Tumors
This is a Phase 1, multi-center, open-label, dose-escalation oncology study of APX3330 in patients with advanced solid tumors.
- Trial name
- APX3330 (NCT03375086)
- Testing
- APX3330
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Apexian Pharmaceuticals, Inc.
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Neoplasms
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no…
- Trial name
- NCT02025803
- Testing
- TAS-114/capecitabine
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Taiho Oncology, Inc.
Neoplasms
Sorafenib/Docetaxel Dose Escalation Trial
The purpose of this study is to: 1.) Evaluate how your body reacts to sorafenib when taken daily (continuously) in combination with docetaxel given every 3 weeks, and to determine the safety of the two drugs together.2.) Measure…
- Trial name
- NCT00562523
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bayer
Hematologic Malignancies, Solid Tumors
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
The purpose of this study is to determine the pharmacokinetic and safety profiles of omacetaxine and its metabolites in patients with relapsed and/or refractory hematologic malignancies or advanced solid tumors following…
- Trial name
- NCT01844869
- Testing
- omacetaxine mepesuccinate
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Breast Cancer, Melanoma (Skin)
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Breast Cancer, Melanoma (Skin), Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003690
- Testing
- alvocidib, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Advanced Cancer
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.
- Trial name
- NCT00708773
- Testing
- Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Chicago
Solid Tumours
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
- Trial name
- NCT00497679
- Testing
- AZD1152
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
AMT-253 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in…
- Trial name
- NCT05906862
- Testing
- AMT-253
- Where
- 7 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Multitude Therapeutics (Australia) Pty Ltd
Advanced Tumors
Study of CPI-100 in Patients With Advanced Tumors
This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).
- Trial name
- NCT03781362
- Testing
- CPI-100, Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Advanced Solid Tumors
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
This open-label, multicenter, dose-escalation study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5509554 in participants with advanced solid tumors which are not amenable to standard treatment.
- Trial name
- NCT01494688
- Testing
- Paclitaxel, RO5509554
- Where
- 7 sites in United States, France
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
A Study of ILB2109 in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced or metastatic solid malignancies.
- Trial name
- NCT05278546
- Testing
- ILB2109
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Innolake Biopharm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.